The biotech company also has a partnership with Sanofi (SNY) for the development, manufacture and commercialization of IgM antibody agonists against inflammation and immunology targets.

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...

High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has been given a consensus rating of “Reduce” by the ten brokerages that are covering the stock, Ratings reports. One equities research analyst ...

Under these changes, it will halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell ...

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...

Red cell alloantibodies are primarily IgG and less often IgM. IgM antibodies readily fix complement and it is these that classically cause the intravascular AHTR. IgG antibodies typically cause ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...